MEGIN Secures $3M in Funding to Drive Global Advancements in MEG Technology

MEGIN, the global leader in Magnetoencephalography (MEG) technology, is excited to announce the successful closing of a $3,000,000 funding round to further its mission of enhancing brain health through groundbreaking innovations.

With over 30 years of experience in the field, MEGIN specializes in detecting and visualizing brain function, working collaboratively with clinicians, scientists, and healthcare organizations around the world.

This newly raised capital will specifically be allocated to advancing research and development initiatives, thereby facilitating the translation of cutting-edge scientific insights into accessible clinical solutions.

MEGIN's unwavering commitment to client-centric solutions underscores their aim to elevate the standard of care for brain health, ultimately improving quality of life for patients globally.

The company's innovative MEG technology is already transforming neuroscience research and clinical decision-making, and with this funding, MEGIN plans to amplify its efforts in raising awareness and utilization of MEG technology.

As MEGIN expands its influence with facilities and a dedicated workforce in Finland, the UK, the USA, and Japan, the company is poised to make even greater strides in neuroscience.

By nurturing strong partnerships with healthcare professionals and organizations, MEGIN is determined to be at the forefront of advancements in brain health, ensuring that patients receive the highest standard of care.

This funding marks a significant milestone in MEGIN’s journey and reflects its commitment to revolutionize the field of neuroscience for better brain health outcomes worldwide.